China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D005 injection (“CMS-D005”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 27 November 2024. The NMPA grants the Group consent to conduct a clinical trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CMS-D005 in healthy and overweight/obese adult subjects in China. CMS-D005 CMS-D005 is a highly active and selective dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Activating glucagon-like peptide-1 (GLP-1) can reduce food intake through central appetite suppression and inhibit gastric emptying to increase satiety to achieve weight loss. Activating GLP-1R can enhance secretion of glucose-dependent insulin and inhibit secretion of glucagon to lower blood glucagon[1], while activating glucagon (GCG) can promote fat catabolism and enhance fat loss, […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 4 November 2024, the New Drug Application (NDA) of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been approved by the Pharmacy & Poisons Board of Hong Kong (PPBHK). The certificate of drug/product registration was obtained on 5 November 2024. The Product is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. About Ruxolitinib Cream Ruxolitinib cream (Opzelura®), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, and is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura®) is also approved in the […]
Recently, Healthcare Executive (“E药经理人”), in collaboration with a leading independent corporate social responsibility consulting agency in China, released the results of 2024 “Chinese Pharmaceutical Listed Companies ESG Competitiveness” series ranking. The ranking aims to recognize Chinese pharmaceutical companies that serve as benchmarks in various aspects of ESG management. By virtue of its continuous efforts in sustainable development and low-carbon initiatives, China Medical System (“CMS” or the “Group”) has been selected into the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Mid-cap Stocks)” ranking for three consecutive years, and has also been included in the inaugural “Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies” ranking. As an active practitioner of the sustainable development concept, CMS steadily responds to the United Nations Sustainable Development Goals, and promotes the deep integration of ESG governance with its macro strategies and business operations. With adherence to high standards of business ethics in its operations, the Group has established a scientific and effective risk identification […]
China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in […]
On September 27, the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association released the “2024 Shenzhen Top 500 Enterprises” list. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 149th, by virtue of its outstanding operational performance, social contributions, etc. Additionally, Shenzhen Kangzhe was also included in the “2024 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2024 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500.” CMS has been deeply rooted in the Chinese pharmaceutical market for over 30 years, developing into a platform company linking pharmaceutical innovation and commercialization. Shenzhen Kangzhe’s inclusion in the “Shenzhen Top 500 Enterprises” for the fourth time not only affirms the Group’s long-term strategic focus on specialty therapeutic fields and its success in providing differentiated products […]
On September 20, 2024, China Medical System (“CMS” or the “Group”) presented its innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) at the 24th Congress of Gastroenterology China in 2024 (“CGC 2024”). This congress brought together numerous domestic scholars and clinical experts in the field of gastroenterology to discuss key topics and advancements in gastroenterology disease research, serving as an important platform for promoting progress in the diagnosis and treatment of gastroenterology diseases in China. CMS develops innovative products with a focus on medical values and clinical needs, striving to provide effective and affordable therapeutic solutions for patients. The innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) is indicated to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy, which not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The Product is a small-volume methotrexate injection with various strengths for the treatment of active rheumatoid arthritis (RA) in adult patients. The Group was granted a certificate of drug registration on 5 August 2024. Methotrexate is recognized internationally as the first choice first-line and anchor drug for RA. The Product is the first methotrexate prefilled injection to treat RA by subcutaneous administration in China, providing a safer, more effective, more convenient and more accurate administration scheme for RA adult patients. According to the communication with NMPA, the bridge clinical trial of the Product in China (the “Study”) aims […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on July 16, two new drug applications (NDA) for Ursofalk® (ursodeoxycholic acid oral suspension) (the “Product”), jointly applied by the Group and Dr. Falk Pharma, have been approved by the National Medical Products Administration (NMPA), covering the following indications: 1) The NDA for the treatment of liver disease associated with a condition called cystic fibrosis in children aged 1 month to 18 years has been approved, which is a rare disease. 2) The NDA for the treatment of dissolution of cholesterol gallstones in the gallbladder (the gallstones must be radiolucent, and the gallbladder function must be intact); cholestatic liver diseases (such as primary biliary cirrhosis) and biliary reflux gastritis has been approved. The application was previously included in the priority review by NMPA’s Center for Drug Evaluation (CDE) for its accordance with […]
In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its “AA” rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating Report. Re-including in S&P Global’s Sustainability Yearbook (China Edition) The S&P Global’s 2024 Sustainability Yearbook (China Edition) has been released. With an CSA score of 51 that surpassing 91% global peers in the industry, CMS stood out among more than 1,700 evaluated Chinese companies to be reincluded in the China Yearbook, becoming one of the five selected companies in the pharmaceutical industry. Source: S&P Global Receiving “AA” once again in MSCI ESG Rating In July, MSCI has released the latest ESG rating report for CMS. The Group […]
On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo. This trial is a randomized, double-blind, placebo-controlled phase III clinical trial evaluating the efficacy and safety of ruxolitinib cream in the treatment of atopic dermatitis in Chinese patients. The trial aims to provide more medical evidence to support the Product’s marketing application in China. The trial, led by Professor Shi Yuling, Vice President of Shanghai Skin Disease Hospital, will be conducted in 20 sites nationwide aiming to enroll approximately 192 atopic dermatitis patients. […]
On June 21, 2024, China Medical System Holdings Limited (“CMS”) was invited to attend the launching ceremony of the “Canteen for Elderly”, a digital meal delivery service project for elderly under the Public Welfare Program named “Hundreds, Thousands and Ten-Thousands Project (百千万工程)” . The ceremony was held in Lianping of Heyuan City, Guangdong Province. CMS responds actively to the “Hundreds, Thousands and Ten-Thousand Project”. With assistance to accelerate the progress of the “Canteen for Elderly” project in Lianping, CMS also participated in the construction of the “Public Library” project to promote the livelihood projects implementation and benefit local population. Canteen for Elderly Elderly meal delivery service is a common livelihood need of elderly people and their families. By donating through the Nanshan Charity Association，CMS participated in the construction of the “Canteen for Elderly in Lianping” project to provide the elderly with warm meals, and effectively improve their quality […]
Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint). The Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy […]
• The Product, a collagen product with bioactive components, is under China’s registrational clinical trial stage. After validated by clinical trials and approved for marketing, it is expected to provide a medical aesthetic solution that could achieve instant physical filling of skin defects, endogenously induce collagen fiber regeneration, and promote tissue repair, achieving safe, natural, and refined rejuvenation effects. • The Product will synergize with CMS Skinhealth’s marketed Korean hyaluronic acid product and the regenerative pipeline products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, providing consumers with comprehensive aesthetic solutions. On June 7, 2024, the subsidiary of China Medical System Holdings Limited (“CMS”), a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement (“the license agreement”) with Shanghai Baiyiyuan Bioengineering Co., Ltd. (“Baiyiyuan Biotech”) for a light medical aesthetic injectable product, Decellularized Extracellular Matrix […]
China Medical System Holdings Limited (“CMS”) persists in showing deep concern for exceptional children and has supported the sustainable development of rehabilitation centers through donations during the past two years. Meanwhile, we have witnessed that many exceptional children successfully integrated into regular schools and received compulsory education with the help of rehabilitation training, laying a solid foundation for their future integration into society and healthy growth. With Children’s Day approaching, CMS again made donations to Shenzhen Nanshan Star Exceptional Children Rehabilitation Center and Shenzhen Nanshan Exceptional Children Care Center through Charity Association of Shenzhen Nanshan. The donation will be directly used for the procurement and renewal of teaching tools and toys in both centers, enhancing the children’s sense of gain, happiness, and security, as well as providing supports for creating good education atmosphere, encouraging outstanding teachers, and improving teaching quality. At yesterday’s event, representatives of CMS interacted […]
9th May 2024 – Can-Fite BioPharma issued a press release, which is summarized as follows: Can-Fite BioPharma Ltd announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for Namodenoson, for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company’s ongoing Phase IIb clinical study. Namodenoson is a small molecule orally bioavailable drug, targeting the A3 adenosine receptor, over-expressed on the surface of liver pathological cells in MASH but not normal cells. This potentially makes Namodenoson an ideal specific candidate for the treatment of MASH. Indeed, in a Phase IIa clinical study Namodenoson, has been shown to reduce hepatic steatosis, inflammation and fibrosis, with an excellent safety profile. Currently Can-Fite is enrolling patients for a Phase IIb clinical study in Europe and in Israel and the IND approval by FDA will allow for the recruitment […]
When the development of a Pharma resonates with the trend of the industry, it is not hard to imagine how fast it will accelerate. Through 32 years of development, CMS has transferred through three stages to continuously build a new CMS for adapting to the external environment. From “selling” drugs when starting up a business, to “owning” drugs by purchasing products’ rights, and now to “creating” drugs via its innovation platform, every step taken by CMS is consistent with industrial development sooner or later. On its 32nd Birthday, with the landings of differentiated innovation fruits, CMS has successfully embarked on the commercialization era of innovative products, continuously building sustainable growth momentum. Persistent innovation investment and transformation bring us the great confidence to embrace “New Future, New Rise”！
On 9th May, the 21st Shenzhen Top Brand and Bay Area Top Brand Event was held grandly, and unveiled series of award lists. The “Kangzhe” brand was awarded the “Shenzhen Top Brand” and “Bay Area Top Brand.” Since 2003, the Shenzhen Top Brand event has been spearheaded by the Shenzhen Industry Association, in collaboration with relevant departments, industry associations, professional institutions, and media organizations to form an evaluation committee. It has fostered a group of Chinese brands with distinct advantages by motivating enterprises in Shenzhen to cultivate and establish esteemed brands. The “Kangzhe” brand participated in the evaluation for the first time. Leveraging its distinctive and professional brand image as well as outstanding innovation achievements, “Kangzhe” brand stood out among 428 applicants and has been awarded as “Shenzhen Top Brand (Bay Area Top Brand)” with high scores in various dimensions, including market position, industry reputation, brand value, and […]
San Diego, CA – [April 11, 2024] – Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations. A second presentation will provide insight into characterization of a repeat-dosing model for preclinical diazepam studies. These findings will be showcased through posters at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format. “These studies represent our continued commitment to improving outcomes for patients with epilepsy,” said Adrian L. Rabinowicz, M.D., Chief Medical Officer. “Our persistent research highlights the efficacy of VALTOCO, and we are delighted to disseminate these additional findings to patients, physicians, and healthcare organizations attending AAN, an event […]
Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adultchronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. China Phase III trial of the Product has demonstrated positive results.The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level. Currently, 4 innovative drugs of CMS have entered intocommercialization Meanwhile, continuous advance of products’ clinical development and registration process such as Desidustat Tablets is expected to enrich the Group’s marketed innovative product portfolio, and generate new driving force to the Group’s sustainable and healthy development. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China (“Macau”) has approved the new drug application of Ruxolitinib Cream (the “Product”) on 11 April 2024. The drug registration certificate was obtained on 16 April 2024. The Product is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Ruxolitinib cream, a novel cream formulation of Incyte’s (NASDAQ:INCY) selective JAK1/JAK2 inhibitor ruxolitinib[1], is the first and only topical JAK inhibitor approved for use in the United States. Ruxolitinib cream is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) […]
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria. HONG KONG, China and WILMINGTON, Del. –1 April, 2024 –China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), and Incyte entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory. Under the terms of the agreement, CMS will make an upfront payment to […]
NMPA has approved the application to conduct a clinical trial evaluating the safety and efficacy of ruxolitinib cream for the treatment of mild to moderate atopic dermatitis (AD) in China. Ruxolitinib cream, a novel cream formulation of Incyte’s (NASDAQ:INCY) selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States. Ruxolitinib cream is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the National Medical Products Administration (NMPA) of the People’s Republic of China has […]
On 6 February, first-line phosphate-lowering Drug Velphoro® (sucroferric oxyhydroxide chewable tablets) has been issued its first prescription in the Gansu Provincial Hospital, which marks that the first iron-based, non-calcium phosphate binder (PB) approved by National Medical Products Administration (NMPA) in China[1] has officially entered clinical application. Velphoro® has become a new option of phosphorus-lowering treatment for CKD dialysis patients in China, and filled the gap of phosphorus-lowering treatment for Chinese paediatric patients aged 12 to 18 years old with CKD stages 4-5 or CKD on dialysis. Velphoro® is a Class 5.1 imported innovative drug, which was approved through the priority review and approval procedure in China in February 2023 for the control of serum phosphorus (sP) levels in adults with chronic kidney disease (CKD) on hemodialysis (HD) or peritoneal dialysis (PD), and meanwhile, for the control of sP levels in paediatric patients 12 years of age and older with […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that CMS-D001 tablets (“CMS-D001”) and CMS-D002 capsules (“CMS-D002”) self-developed by the Group have been granted approvals for drug clinical trials recently by National Medical Products Administration of the People’s Republic of China (“NMPA”). NMPA agrees to conduct (i) a randomized, double-blind, placebo-controlled phase I clinical study of single or multiple dose escalation and food effects (open) to evaluate the safety, tolerability, pharmacokinetics and efficacy of CMS-D001 in healthy subjects and patients with plaque psoriasis; and (ii) a randomized, double-blind, placebo-controlled phase I clinical study of single or multiple dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D002 in healthy adult premenopausal female subjects. CMS-D001 CMS-D001 is a highly selective TYK2 (tyrosine kinase 2) inhibitor. TYK2 is a member of the JAK kinase family, which is an important component in immune cell signaling. CMS-D001 […]
Achievement of ACTIMIS primary endpoint, confirming the safety of glenzocimab in acute ischemic stroke patients Reduction in the rate and severity of intracranial hemorrhages and of mortality in glenzocimab-treated patients Acticor Biotech (FR0014005OJ5 – ALACT), a clinicalstage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, focusing stroke, announces the publication of phase 1b/2a clinical results of ACTIMIS study in The Lancet Neurology Journal on 23rd, January. The manuscript is entitled: Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a phase 1b/2a randomized, placebo-controlled, trial The ACTIMIS clinical trial evaluated glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with an Acute Ischemic Stroke（AIS）. This publication displays the full analysis of ACTIMIS results. The key results presented in the manuscript are: – Achievement of ACTIMIS primary endpoint, confirming the safety of […]
Obtained Velphoro®, an innovative drug (sucroferric oxyhydroxide chewable tablets) which has been newly included in the National Reimbursement Drug List. It is a new generation of iron-based, non-calcium PB and approved in China for the control of serum phosphorus (sP) levels in adults with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis, and for the control of sP levels in paediatric patients 12 years of age and older with CKD stages 4-5 (defined as glomerular filtration rate <30mL/min/1.73 m²) or CKD on dialysis. The Product has been approved in China, and it will expand the Group’s marketed innovative product portfolio, and will synergize with the marketed products XinHuoSu (recombinant human brain natriuretic peptide for injection), Plendil (felodipine sustained-release tablets) and Desidustat tablets (intended to treat anemia in CKD patients) which is in the clinical development stage in terms of resources network. It is expected to have a positive […]
Obtained an exclusive license to commercialize Polycaprolactone Microsphere Gelfor Injection and Calcium Hydroxylapatite Microsphere Gel for Injection in Mainland China, Hong Kong, Macao and Taiwan; Through regenerative materials’degradation, these two products can stimulate human body’s collagen regeneration and produce a dual effect of “fill and regeneration repairing”. In addition, these two products are suitable for different facial problems respectively, providing personalized solutions for consumers; The products will synergize with CMS Skinhealth’smarketed Korean hyaluronic acid product, Vmonalisa, and the pipeline product Poly-L-lactic Acid Microparticle Filler Injection, creating a professional and three-dimensional product matrix and providing comprehensive facial solutions to consumers. On January 16, 2024, the subsidiary of China Medical System Holdings Limited (“CMS”) – a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd. (“Xihong Biopharma”) for two regenerative medical aesthetic products, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel […]
On 29 December, 2023, China Medical System Holdings Limited (“CMS”) is pleased to announce that PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by CMS, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and HEALTHY GOAL LIMITED (“Legend Fund”), has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. ( defined as “Singapore manufacturing plant ”). The Singapore manufacturing plant has advanced manufacturing machines, equipment and first-class infrastructure. It had been approved by Health Sciences Authority of Singapore (HSA), U.S. Food and Drug Administration (FDA) and Therapeutic Goods Administration of Australia (TGA). It will serve as the plant and site for PharmaGend to carry out pharmaceutical formulation, finishing, and packaging business, accelerating the […]
Recently, the fourth annual Environmental, Social, and Governance (ESG) Forum and Awards Ceremony hosted by Cailian Press ended successfully. China Medical System (“CMS”), with its long-term efforts and outstanding performance in the ESG field, was honored with the “2023 Cailian Press Zhiyuan Award – Pioneer in Corporate Governance.” The Cailian Press Zhiyuan Award aims to select representative companies that have business value and social influence in the ESG field and have contributed to the sustainable development. Specifically, the “Pioneer in Corporate Governance” award evaluates the comprehensive performances in corporate governance and selects companies with leading practices in ESG strategy, governance, profitability, competitiveness, and related honors. Upholding the ESG vision of becoming a world-leading sustainable pharmaceutical enterprise, CMS is dedicated to integrating sustainable development concepts into its overall strategy and daily operation. CMS has established a scientific and effective governance structure with clear responsibilities, and continuously promotes stakeholder engagement to optimize its internal […]
Recently, the innovative drug Diazepam Nasal Spray (VALTOCO) has issued its first prescription in the Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), which marks that the first Diazepam Nasal Spray in China has officially entered clinical application. It satisfies the unmet clinical needs of epilepsy emergency rescue outside the medical setting and brings a new acute treatment scheme for the seizure clusters/acute repetitive seizures of children and adults aged 6 and above with epilepsy. (Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences) issued the first prescription of Diazepam Nasal Spray (VALTOCO)) So far, three innovative drugs successfully approved for marketing this year have officially entered the national scale clinical application, marking another important milestone for the company to promote the commercialization of innovative products. On June 7, 2023, Diazepam Nasal Spray received approval from the National Medical Products Administration of China (NMPA). It is used for the seizure […]
On December 21, 2023, at the award ceremony of the “8th Global Investment Carnival” hosted by GuruClub, China Medical System (867.HK) stood out among over a hundred Hong Kong-listed companies with its sound business performance, outstanding innovation achievements and solid returns for shareholders, winning the award of ” Most Popular Southbound Stock Connect Company”, continuously enhancing its reputation in the capital market. The “Golden GuruClub Awards” annual outstanding company selection by GuruClub is one of the most influential rankings in the capital market. The ” Most Popular Southbound Stock Connect Company” award aims to commend listed companies with health corporate governance, leading industry position, promising business structure, and ability to provide sustainable and solid value returns for investors. Wining this award represents the capital market’s recognition of CMS’s outstanding performance this year. Since its listing on the main board of the Hong Kong Stock Exchange in 2010, CMS has been adhered to compliant operation and innovation development under continuously improved governance system. The company has maintained steady performance growth over years, with its annual compound growth […]
At 23:59 on December 18th, a M6.2 earthquake with a depth of 10 kilometers occurred in Jishishan County, Linxia Prefecture, Gansu Province. The earthquake affected 22 villages and towns in Qinghai Province within a range of 50 kilometers from the epicenter, causing casualties and property damage in many areas of Gansu and Qinghai. The disaster in this cold winter is touching the hearts of the whole nation. Merciless disaster, the world is love. The local governments and public welfare organizations attach great importance to this earthquake and provide necessary assistance and support to residents in the disaster area. CMS actively and rapidly responded to support the rescue work in the earthquake-stricken areas. After understanding the needs of the disaster area at the first time, CMS urgently purchased a batch of emergency relief materials, including Halal meals, cold-proof clothing, heating equipment, sanitary supplies, etc. CMS rushed to the rescue of Gansu and Qinghai with actual […]
The 10th CAAE International Epilepsy Forum hosted by the Chinese Anti-Epilepsy Association was grandly held in Nanchang from 15th to 17th December, 2023. Over 1700 authoritative experts from China and other countries/regions gathered together to exchange and discuss the hot topics in international epilepsy research and the frontiers of neuroscience, share academic feasts, and explore domain development. Adhering to its mission of providing competitive products and services to meet unmet medical needs, China Medical System (“CMS”) showcased its innovative drug Diazepam Nasal Spray (VALTOCO) at the conference. VALTOCO provides a more optimal and convenient choice for the acute treatment of cluster/acute recurrent seizures in domestic epilepsy patients. CMS’s Diazepam Nasal Spray (VALTOCO) Debuts at the 10th International Epilepsy Forum of CAAE Perseverance Leads to Success, Epilepsy Emergency Rescue Acquiring New Progress During the three-day conference, many scholars brought fascinating academic reports on the hot and difficult issues in current […]
Recently, China Medical System’s innovative drug ILUMETRI (Tildrakizumab Injection) has issued its first prescriptions for psoriasis patients who meet the treatment requirements in multiple hospitals located in different Chinese cities, including the Dermatology Hospital of the Chinese Academy of Medical Sciences, the Third Affiliated Hospital of Sun Yat-sen University, the Dermatology Hospital of Southern Medical University, and the First People’s Hospital of Foshan City. With the official launch of ILUMETRI’s nationwide drug supply, ILUMETRI officially stepped into large-scale clinical application, providing better choices for the long-term treatment and disease management among psoriasis patients in China. On May 26, 2023, ILUMETRI (Tildrakizumab Injection) was approved for marketing by the National Medical Products Administration of China for the treatment of adult patients who have moderate to severe plaque psoriasis and are suitable for systemic therapy or phototherapy. On December 13th, the “National Catalogue of Medicines for Basic Medical Insurance, Work Injury Insurance, […]
Innovative drugs VALTOCO (Diazepam Nasal Spray)，ILUMETRI (Tildrakizumab Injection) and rare disease drug Tetrabenazine Tablets have been newly included in China’s National Reimbursement Drug List(NRDL), XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection) has continued to be included in NRDL. The Group actively responds to national policies to promote innovative products to be included in the NRDL. Up to now, 3 innovative drugs that have been approved for marketing (Diazepam Nasal Spray, Tildrakizumab Injection and Methotrexate Injection-psoriasis) have all been included in the NRDL, further improving the accessibility and affordability of the drugs and allowing innovative products to benefit more patients. The new/continued inclusion of the 4 products in the NRDL will be conducive to promoting the market coverage of the products and building professional brand power, and will have a positive effect on the Group’s business development. China Medical System Holdings Limited (“CMS” or “the Group”) is pleased to […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration (NMPA) has approved the application to conduct a clinical trial evaluating the safety and efficacy of Ruxolitinib Cream (the “Product”) for the treatment of non-segmental vitiligo on 11 December 2023. Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million and 6.5 million vitiligo patients in China and the eleven Southeast Asian countries, respectively. Non-segmental vitiligo patients account for approximately 85% of them. If approved in Greater China and Southeast Asia, it may bring a novel therapeutic option to patients with non-segmental vitiligo in the area and satisfy the clinical need of topical drugs combining safety and efficacy. The Product is not approved by the NMPA for any indication in […]
On December 6th, the 8th Zhitong Finance Capital Market Annual Conference, jointly organized by Zhitong Finance and ROYALFLUSH INFO Finance, was grandly opened in Shenzhen. At the highly anticipated “Listed Company Selection and Awards” session, China Medical System Holdings Limited (“CMS”) (867.HK) was awarded the “Most Socially Responsible Listed Company” due to its high emphasis and active practices on social responsibility. The “Listed Company Selection” involved over a thousand listed companies, aiming to select outstanding examples among Hong Kong/US listed companies through rigorous indicator analysis, online voting, and expert evaluation. The “Most Socially Responsible Listed Company Award” aims to recognize listed companies that strive to practice social responsibility, actively fulfill their responsibilities towards consumers, communities, and the environment, and make positive contributions in areas such as charitable donations, targeted poverty alleviation, and ecological protection. For many years, CMS has been actively fulfilling the responsibilities and commitments of pharmaceutical […]
The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection. The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China. The China bridge clinical trial of the Product’s RA indication reached the main endpoint; The results of secondary efficacy indicators suggest that the efficacy of the product is significantly better than that of MTX tablets or there is a trend of better. The product also has some advantages over MTX tablets in gastrointestinal safety. MTX is recognized internationally as the first choice first-line and anchor drug for RA. As a small-volume MTX prefilled injection with various strengths, the Product is expected to provide a safer, more effective, more convenient and more accurate administration scheme for active […]
On November 25, 2023, the “Innovative Medicine Brings Brighter Future of Skin Health – 2023 Frontiers Conference on New Developments of Dermatological Treatment” was grandly held in Sanya, Hainan Province. The conference was co-organized by Hainan Lecheng Real World Research Institute and Hainan Boao Lecheng International Medical Tourism Pioneer Zone Administration. It brought together many top domestic scholars and clinical experts in the dermatology field to share in-depth research on the pathogenesis, diagnosis and treatment of psoriasis and vitiligo, providing more new technologies and therapies for the clinical treatment of the related diseases. The innovative drug for psoriasis treatment, ILUMETRI (Tildrakizumab Injection) made its debut at the conference, demonstrating CMS’s ability to empower the continuous transformation of innovative outcomes into diagnosis and therapeutic practice. Gathering leading academic forces Exchanging new developments in dermatological treatment More than 200 medical experts in the field of psoriasis and vitiligo […]
438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the United-States, Europe, Israel and United Kingdom Confirmation of clinical results communication for the second quarter 2024 Acticor Biotech (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced the timely completion of enrollment in the ACTISAVE Phase 2/3 clinical trial in patients with acute ischemic stroke (AIS) on November 7, 2023. Gilles Avenard, General Manager of Acticor Biotech, declares: “We are pleased with the completion of the enrollment of our clinical study evaluating the efficacy of glenzocimab in 438 stroke patients exactly on schedule. We eagerly anticipate sharing the outcomes of this world-class study in the second quarter of 2024. This achievement bolsters our commitment to delivering an innovative drug for the treatment of cardiovascular emergencies, that is strengthened, moving forward at every milestone of […]
Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary endpoints met at Week 52 after 9-months off treatment On 13 November, Blueberry Therapeutics Limited (“Blueberry” or “the Company”), a pharmaceutical company focused on developing innovative, topical nanomedicines to treat dermatological conditions, announced that BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial (BBTAF202) in patients with onychomycosis, showing superiority over placebo (vehicle) with a high level of statistical significance. BBTAF202 was a European trial conducted in 111 subjects with mild to moderate distal subungual onychomycosis (DSO) of the toenail, recruited from sites in Germany, Poland and the Czech Republic. This trial assessed the efficacy, safety and pharmacokinetics of 3 months twice-daily treatment of BB2603-10 versus vehicle, along with 2 lower formulation strengths of BB2603-3 and BB2603-1. A 3‑month treatment duration is considerably shorter than for […]
On 26th October, the prescriptions of China Medical System(CMS)’s innovative drug, named Metoject (Methotrexate Pre-filled Injection), have been issued for the first time in several hospitals located in different Chinese cities. It marked Metoject, the first Methotrexate (MTX) pre-filled injection for subcutaneous administration for the treatment of psoriasis in China, officially stepped into the clinical application stage and stepped into the new era of psoriasis therapy, bringing a novel and better traditional treatment option for psoriasis patients. On 24th March this year, Methotrexate Injection was approved for marketing in China for the treatment of severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids. Metoject (Methotrexate Pre-filled Injection), is available in small-capacity strengths with high concentration, and adopts a new MTX delivery method, subcutaneous administration to increase its bioavailability. Featured with pre-filled syringe, Metoject allows patients to administer independently once […]
On September 25th, the list of “2023 Shenzhen Top 500 Enterprises” was officially announced. With outstanding performance in terms of overall scale, operating efficiency, creative capabilities and other comprehensive strengths, Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 143rd on the list. Shenzhen Kangzhe was also listed on the “Top 100 Social Contribution List of 2023 Shenzhen Top 500 Enterprises”. The “2023 Shenzhen Top 500 Enterprises” list is jointly released by the Shenzhen Enterprise Federation and Shenzhen Entrepreneurs’ Association. It is one of the most influential and authoritative rankings for Shenzhen enterprises. The list primarily evaluates participating companies based on various production and operation indicators where all the listing companies are the backbone of Shenzhen’s economic and social development. Due to Shenzhen’s rapid economic growth and the Group’s solid operational achievements, Shenzhen Kangzhe has been […]
Recently, the results of “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness in 2023” series ranking were released. This activity was jointly launched by Healthcare Executive(“E药经理人”) and a leading independent corporate social responsibility consulting agency in China. China Medical System (“CMS”), with its years of efforts and outstanding performance in ESG management, was awarded the title of “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness in 2023”. With the core evaluation dimensions on companies’ ESG transparency and management performance, the “Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness” aims to select representative pharmaceutical listed companies in sustainable development management, providing benchmarks for the upgrade and sustainable development of China’s pharmaceutical industry. As an active practitioner of sustainable development, CMS has established a scientific governance structure and a refined control system. The Group actively facilitates the profound integration of ESG concept into its macro strategies and business […]
Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. The Product has a clear mechanism of action, which is conducive to exerting brain cytoprotection effects. Meanwhile, the Product has a rapid anti-depression and anti-anxiety function, and is expected to become the first new type of brain cytoprotectant that treats both stroke and post-stroke depression. The product will enrich the cardio-cerebrovascular (including the central nervous system) pipeline of the Group. After approved for marketing in China, it is expected to meet the clinical needs of drug with both safety and efficacy, providing new treatment options to ischemic stroke patients in China. On August 24, China Medical System Holdings Limited (“CMS” or the “Group”) announced that the Group entered into a Collaboration Agreement (the “Agreement”) with Nanjing NeuroDawn Pharmaceutical Co. Ltd. (“NeuroDawn Pharmaceutical”), for anti-ischemic stroke brain cytoprotectant […]
On 19 August, at the Launching Conference for the Pilot Project of ruxolitinib cream, China Medical System Holdings Limited (“CMS”) announced that ruxolitinib cream, has been approved by the Health Commission and Medical Products Administration of the Hainan Province, under the early access program in the Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Through this program, the first prescription of ruxolitinib cream was filled in China at the Boao Super Hospital, a designated medical institution of Hainan, for an eligible vitiligo patient. The Pilot Zone allows individuals with urgent unmet needs to access innovative drugs, medical devices and technologies that have not yet been approved by NMPA in China but that have been approved by regulatory authorities overseas. Through the program, Chinese patients can apply to use ruxolitinib cream […]
Recently, Typhoon Doksuri has caused extreme rainfall in Beijing, Tianjin, Hebei, and other areas, leading to severe floods and geological disasters with casualties and significant property losses. China Medical System Holdings Ltd(“CMS”) quickly responded and made donation of RMB 1 million to the China Charity Federation on August 4th, to support emergency rescue and post-disaster reconstruction in severely affected areas of Beijing, Tianjin and Hebei, etc. At the same time, we pay the highest respects to all the heroes who are participating in the front-line disaster relief efforts! Let us unite and work together to tide over the difficulties. May the affected areas could be recovered as soon as possible.
Recently, MSCI (Morgan Stanley Capital International), the world’s largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the “Group”), who achieved an “AA” rating and surpassed 75% of global peers with leading ESG management practices. MSCI is one of the most widely used, influential, and referenced rating companies in the global market. Based on a scientifically rigorous evaluation system, it evaluates companies’ risk control performance and sustainable development potential comprehensively from various aspects such as environment, human capital, health accessibility, product safety and quality, and corporate governance. MSCI-ESG rating results have been regarded by global investors as an important non-financial basis for investment decision-making. Being back to the “AA” rating, reflects the full recognition of the Group’s ESG management practices by the international authoritative rating company. The Group deeply integrates the concept of sustainable development into its operations […]
– Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023 – Namodenoson is in pivotal Phase 3 study for the treatment ofadvanced hepatocellular carcinoma (HCC) – A patient from the prior Phase 2b study is cancer-free >6 years following initial treatment with Namodenoson Can-Fite announced its abstract titled “A novel approach for the treatment of advanced hepatocellular carcinoma (HCC)” is one of the highest scoring abstracts and has won the prestigious Breakthrough Abstract Award from Conquer Cancer®, the ASCO Foundation, and the 2023 ASCO Breakthrough Program Committee. Can-Fite’s Chief Scientific Officer, Founder, and Executive Chairman, Dr. Pnina Fishman, will present the poster at the ASCO Breakthrough Meeting which will take place August 3 – 5, 2023 in Yokohama, Japan. Namodenoson has received significant acknowledgment in the scientific and medical community, as evidenced […]
Recently, S&P Global, the world’s leading corporate sustainability assessment institution, has officially released the first “Sustainability Yearbook 2023 (China)”. China Medical System Holdings Limited (“CMS” or the “Group”), standing out from many outstanding companies, was successfully included in this Yearbook. Previously, S&P Global updated CMS’s Sustainability Score to 53, surpassing 92% of the global peers participating in this evaluation, and it is significantly ahead of the industry average. S&P Global has published global versions of the “Sustainability Yearbook” for 16 consecutive years, and has received extensive attention and recognition. This year, S&P Global published the “Sustainability Yearbook (China)” for the first time, aiming to identify and recognize Chinese companies that have great sustainable development performance in different industries. Nearly 1600 Chinese companies from 60 industries were included in the selection pool of the yearbook, but only companies that scored within the top 15% of their industries and achieved a S&P […]
On June 12, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on June 7 2023, the New Drug Application (NDA) of Diazepam Nasal Spray (the “Product”) received approval from the National Medical Products Administration of China (NMPA). The Product is the first diazepam nasal spray in China, and it is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older. The Product is a proprietary formulation of diazepam administered through the nasal mucosa, and has high bioavailability, outstanding absorbability, tolerance and reliability. Product formulation incorporates a combination of Vitamin E-based solvents and Intravail® absorption enhancer. Intravail® transmucosal absorption enhancement technology enables the non-invasive delivery of a broad range of proteins, peptides and small-molecule drugs. The results of the Product’s […]
CMS Obtained Exclusive License of a Regenerative Medical Aesthetic Product On May 30, the subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) – a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd.(“Xihong Biopharma”) for Poly-L-lactic Acid Microparticle Filler Injection (the “Product”). In accordance with the license agreement, CMS Skinhealth obtained an exclusive license to promote, market and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The exclusive license period shall begin from the date of the approval of the registration certificate of class III medical device of the Product in Mainland China and shall last until the tenth anniversary of the aforementioned date of approval. Upon the expiration of the aforementioned term, the license period may automatically be extended for another period of ten years thereafter if […]
On May 30, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMETRI is a humanized lgG1/κ monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMETRI has patents on composition and formulation in China. The results of the extended study of its Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level […]
On May 15, Hang Seng Indexes Company newly launched the Hang Seng Innovative Drug Index, in which CMS has been included. The purpose of setting the Hang Seng Innovative Drug Index is to reflect the performance of companies engaged in the research， development and manufacture of innovative drugs，and are listed in Hong Kong. The index uses the Constituents of the Hang Seng Composite Index as the universe. Each eligible security will be assigned with a Relevance Score according to its business exposure to the innovative drug industry. The top 40 securities with the highest Relevance Score Rank will be selected as constituents. Being included in the index reflects the capital market’s recognition of the Group’s comprehensive strength of innovative R&D. After 5 years of efficient innovative products layout, CMS has collaborated with around 20 global biotech companies and biopharma and established a differentiated innovative pipeline with 30 innovative products, mainly […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the tetravalent bispecific anti-VEGFA (vascular endothelial growth factor A) / ANG2 (angiopoietin 2) antibody for intravitreal injection (the “Tetravalent Bispecific Antibody Product”) has been granted an approval for drug clinical trials issued on 27 April 2023 by National Medical Products Administration of the People’s Republic of China (“China”) (NMPA) and agreed to conduct the clinical trials in neovascular age-related macular degeneration (nAMD). The Tetravalent Bispecific Antibody Product is a Class 1 Innovative Biological Product with a unique nano-antibody design bearing specific targeting VEGFA and ANG2, which can effectively inhibit abnormal neovascularization through two different pathways, for treatment of the ocular fundus neovascular diseases. The Tetravalent Bispecific Antibody Product enjoys the differentiation advantages of high affinity, strong inhibitory activity, high preparation concentration, good stability and low dosing frequency. It will provide a safer and more effective treatment option for patients with ocular fundus neovascularization, possessing important […]
On April 7th, China Medical System Holdings Limited (“CMS” or “the Group”) signed a strategic collaboration agreement with Haikou National High-tech Industrial Development Zone Management Committee (“Haikou National High-tech Zone”), and the Management Bureau of Boao Lecheng International Medical Tourism Pilot Zone (“Lecheng Pilot Zone”) to promote the introduction of the products in Lecheng and manufactured in Haikou of the Group’s international innovative drugs and medical devices. Leaders including Ni Qiang, Deputy Governor of Hainan Province and Director of the Working Committee of the Provincial Party Committee for the Free Trade Port, Liu Liwu, Director of the Hainan Provincial Ministry of Industry and Information Technology, Jia Ning, Director of the Hainan Provincial Medical Insurance Bureau and the Boao Lecheng Management Bureau, Zhu Ning, Director of the Hainan Medical Products Administration, Deng Lisong, Member of the Standing Committee of the Haikou Municipal Party Committee and Deputy Mayor, Feng Guang, Deputy Director […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 27 March 2023, the Group through the Company’s Southeast Asian business (“Rxilient”) companies Rxilient Biotech Pte. Ltd. (“Rxilient Biotech”) and Excellmab Pte. Ltd. (“Excellmab”) entered into a Shareholders’ Agreement (the “Shareholders’ Agreement”) with Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司, “Junshi Biosciences”), pursuant to which Junshi Biosciences will subscribe for the shares newly issued by Excellmab in a non-monetary manner to obtain 40% equity interest. Subject to the fulfillment of the conditions precedent agreed under the Shareholders’ Agreement, Junshi Biosciences will substantially perform its capital contribution obligations and plans to enter into an Exclusive License Agreement (the “License Agreement”) with Excellmab in accordance with the text agreed upon by the parties at the time of entering into the Shareholders’ Agreement, granting Excellmab the […]
China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 24 March 2023, the New Drug Application (NDA) of Methotrexate Injection (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids. In January 2022, the NDA was granted a priority review procedure as it complied with the “shortage of products with urgent clinical need” in China. Methotrexate (MTX) has anti-inflammatory, anti-proliferative and immunomodulatory effects, and is currently one of the most effective traditional drugs for the treatment of psoriasis. However, oral MTX has poor patient compliance due to relatively large gastrointestinal side effects. The Product is administered subcutaneously (this form of administration was recommended by domestic and foreign guidelines), which can increase […]
On February 24, the Hong Kong Listed Company Development Forum and the Ranking of the 10th “Top 100 Hong Kong Listed Companies” Awards Ceremony were grandly announced, and China Medical System Holdings Limited (“CMS” or the “Group”) was selected for “Top 25 Listed Pharmaceutical Companies” for the third consecutive year. It reflects the capital market’s high recognition and confidence of the Group’s investment value and development prospects. The selection of “Top 100 Hong Kong Listed Companies” was initiated in 2012，and had become an new benchmark of investment in Hong Kong capital market. The “Top 25 Listed Pharmaceutical Companies” are selected based on the comprehensive evaluation of five indicators: total market value, turnover growth, net profit after tax, return on equity and return on investment, aiming to create authoritative and credible ranking lists of Hong Kong listed pharmaceutical companies. After years of products investment and R&D efforts, CMS has already become […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 15 February 2023, New Drug Application of the Group’s innovative patented drug methylthioninium chloride enteric-coated sustained-release tablets (“Methylthioninium Chloride Enteric-coated Sustained-release Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). Methylthioninium Chloride Enteric-coated Sustained-release Tablets is an oral diagnostic drug, being designed to significantly increase the detection rate of non-polypoid colorectal lesions by enhancing the visualization of the colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The Product obtained positive results of its Phase Ⅲ clinical trial in China. The primary study endpoint – the detection rate of non-polypoid colorectal lesions, defined as the proportion of subjects with at least one histologically proven nonpolypoid colorectal lesion, was 51% in the test group (the […]
On December 28, the rank of “the 12th China’s Top Listed Companies by popularity 2022” was grandly released. China Medical System Holdings Limited (“CMS” or the “Group”) won both the awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”. The rank of Top Listed Companies by popularity was held by The National Business Daily， aiming to build reputation and create value for the capital market. This year the selection went through four stages, these are public nomination, big data screening, model screening, and institution + public voting. After more than 3 months of selection, nearly 3,000 listed companies were nominated, and 15 major awards were finally released. Winning both awards reflects the comprehensive strength of CMS in the bio-pharmaceutical industry and demonstrates high affirmation from capital market on its quality development. In recent years, CMS has driven its development through innovation, continuously strengthened the open platform, and joined hands with global biotechnology innovation companies to develop differentiated innovative products to meet […]
December 22, 2022, the 6th China IR Annual Awards was grandly held, and China Medical System Holdings Limited (CMS) was awarded “Best Information Disclosure Award”! China IR Annual Awards aims to honor outstanding IR teams and individuals of listed companies that have made contributions to promoting industry reformation and development. The selection covers more than 600 companies listed in Mainland, Hong Kong and US stock markets. China IR Annual Awards is reported by more than 30 mainstream financial media with tens of millions hits on the internet, and it has become one of the most influential selections in the IR field of listed companies in China. CMS always attaches great importance to transparent, timely and effective communication with investors. Based on its high standard corporate governance, CMS constantly improves its information disclosure system and quality, and enriches information disclosure channels. On the basis of ensuring mandatory information disclosure in accordance […]
December 19, 2022, “the Seventh Zhitong Caijing Hong Kong Stock Connect listing Company Award” ceremony was grandly held in Hangzhou Intercontinental Hotel, CMS was honored to win “Best Hong Kong Stock Connect listing Company”! The ceremony was held by Zhitong Caijing, China Galaxy Securities and RoyalFlush. “Best Hong Kong Stock Connect listing Company” aims to reward Hong Kong Stock Connect listing companies with healthy governance structure, leading industry position and steady business operation, that can provide investors with continuous and stable value returns. This honor demonstrates the attention and affirmation of capital market on the future prospect and investment value of CMS. Since being listed, CMS has always adhered to high-standard corporate governance and efficient operation system, and continued to create high returns for shareholders and other stakeholders. In the past ten years (2012-2021), both the CAGRs of its sales revenue (In the case that all medicines were directly sold by the Group) and net profit exceeded 20%; meanwhile, the Group maintained high dividend payout ratio of 40% net profit and […]
December 16, 2022, the selection results of Guruclub “Golden Award”- Greater China best listed companies awards – were grandly announced, CMS was selected as the winner of the “Annual Growth Value Awards (for Large-caps)”. The selection principle of the “Golden Award” is based on “global vision, betting on China”, aiming to create a list of listed companies with the most referential value in the investment industry, covering listed companies in Shanghai, Shenzhen, Hong Kong, and the United States. The winners of ” Annual Growth Value Awards (for Large-caps)” were selected through strict quantitative data analysis and expert review. The award is aiming to commend listed companies not only with continuous self-strengthening ability in its development with vitality, growth ability, and core competitiveness, but also can continue to create values for the country and society. This award represents capital market’s full affirmation of CMS’s corporate value and future growth. CMS has […]
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the Group’s innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets (“the Product”) has obtained positive results for its Phase III clinical trial in China. This is another breakthrough for the Product after CMS had efficiently completed the enrollment of all 1,802 subjects for its China Phase III Clinical Trial in July this year, of which only 6 months (including the Spring Festival Holiday) was taken. The Group will actively move forward the Product’s new drug application (NDA) in China. In this China Phase III clinical trial, Methylthioninium Chloride Enteric-coated Sustained-release Tablets was compared to placebo with the purpose of assessing its safety and efficacy in the improvement of histologically confirmed non-polypoid colorectal lesions in subjects undergoing screening or surveillance colonoscopy for colorectal cancer. The research was led by Beijing Friendship Hospital, Capital Medical University and conducted in […]
The Board of Directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 2 December 2022, the Group through a subsidiary of the Company – a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte (Nasdaq:INCY) (“Incyte”), a global biopharmaceutical company, for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases (“Ruxolitinib Cream” or the “Product”). In accordance with the License Agreement, the Group through CMS Skinhealth gained an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The […]
Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited (“CMS”) . CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average. This result shows the Company’s outstanding achievement from its active integration of ESG governance into strategic development and daily operation. S&P Global CSA is the global leading assessment tool of corporate sustainability practices initiated by S&P Global. S&P Global CSA provides comprehensive evaluation on corporate sustainability performance, and the Company’s identification and management abilities of potential opportunities and challenges by considering factors, such as corporate economy and governance, environment protection, and social responsibility. S&P Global CSA has been regarded, by stakeholders, as one of the most important references for making business or investment decisions. Based on a well-established, […]
Recently, the results of a selection of “TOP20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies” were announced. This activity was guided by China Pharmaceutical Enterprise Management Association and jointly launched by China’s leading independent consulting agency for corporate social responsibility. China Medical System(“CMS”) was included in the top 20 list due to its long-term unremitting efforts and outstanding performance in ESG governance. The Selection of “TOP20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies” takes ESG information disclosure transparency and ESG material issue management performance as the core evaluation dimensions, to explore the Chinese pharmaceutical listed companies that are most representative in ESG management and have ESG investment value, providing experience and benchmarks for the transformation and upgrading of China’s pharmaceutical industry and building sustainable industrial competitiveness. Adheres to the concept of sustainable development, CMS continuously improves ESG management and practices in all aspects of the Group’s operations. CMS has established an […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 7 October 2022, the Group through a subsidiary of the Company – a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a License, Collaboration and Distribution Agreement (the “License Agreement”) with BMI KOREA CO., LTD. (“BMI”), a South Korean company, for the type A botulinum toxin 100 units vacuum dried powder for solution for injection (the “BMI Botulinum Toxin Product” or the “Product”). In accordance with the License Agreement, the Group through CMS Skinhealth gained an exclusive license to develop, register, import and commercialize the BMI Botulinum Toxin Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The License Agreement will commence on its effective date and continue to be valid until the tenth anniversary of the […]
On September 21, Shenzhen Enterprise Federation and Shenzhen Enterprise Directors Association released the list of “2022 Shenzhen Top 500 Enterprises”. With outstanding performance in terms of business scale, employees scale, tax payment, social responsibility, etc., Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 130. As a local enterprise born and grown in Shenzhen, Shenzhen Kangzhe capitalizes on the global upstream and downstream resources accumulated by the Group to fulfill the mission of “Providing competitive products and services to meet unmet healthcare and aesthetic needs” and benefit more patients with accessible and affordable quality medicines. Being once again selected for the “Shenzhen Top 500 Enterprises” shows the recognition of Shenzhen Kangzhe’s comprehensive strength and brand value. In the future, CMS will continue to proactively seize the opportunities presented by the construction of the Guangdong-Hong Kong-Macao Greater Bay Area and the Pioneering Demonstration […]
Recently, the results of the selection of “Top 20 Competitive Chinese Pharmaceutical Listed Companies in 2022” were announced, China Medical System(“CMS”) stood out from the listed pharmaceutical companies and was once again included in the top 20 list. This activity was guided by China Pharmaceutical Enterprise Management Association and jointly launched by HealthCare Executive and Hejun Consulting. The selection of “Top 20 Competitive Chinese Pharmaceutical Listed Companies” has been organized for the 14th consecutive year. It evaluates Companies with ECIRM model of “Entrepreneur, Capital, Industry, Resources and Management” and identifies the ones with comprehensive competitive strength and being able to flexibly adapt its strategy to the industry trend. CMS takes innovation development to adapt to the complex and rapid changing external environment. With 30 years of accumulated commercialization resources in China, including extensive academic resources and deep market understanding, CMS is able to identify unmet clinical needs with sharp business […]
August 26, 2022, Gelesis issued a press release, which is summarized as follows: On August 25, Gelesis released a poster presentation at the International Congress of Endocrinology in Singapore. The LIGHT-UP study evaluated the safety and efficacy of GS200, an investigational oral hydrogel, which was designed to emulate the properties of ingested raw vegetables, with slightly different mechanical properties compared to Plenity (GS100). The LIGHT-UP study was conducted over 25 weeks in 254 participants with prediabetes or type 2 diabetes and a BMI of 27-40 kg/m2. It met its primary endpoints and GS200 reported a highly favorable categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications. One out of three GS200-treated adults were “super responders,” losing at least 10% of their body weight and on average losing 13% (~30 pounds), or 7 inches off their waist circumference […]
In August 2022, the COVID-19 pandemic struck Tibet Autonomous Region and the pandemic situation was complex. China Medical System Holdings Limited (“CMS”) has paid close attention to the pandemic condition, and in order to support the pandemic prevention and control, its subsidiary Tibet Kangzhe Pharmaceutical Development Co. (“Tibet Kangzhe”) has donated several kinds of epidemic prevention materials to the local government, schools and communities, including medical protective clothing, N95 masks, medical gloves and ethanol disinfectant, etc., while quickly organizing its staff to join the volunteer groups to support the transport of anti-epidemic supplies, nucleic acid testing and pandemic prevention propaganda. The Group will continue to pay close attention to the pandemic condition and actively participate in the pandemic prevention and control works, so as to fulfill our mission and responsibility with concrete actions. Under the effective control of the Tibetan government, we look forward to a victory against the pandemic in Tibet.
Namodenoson induced a complete response with disappearance of all metastases in a patient who will now continue the treatment under a compassionate use program in Romania Can Fite’s Phase III pivotal study is open for patient enrolment 23th August, 2022- Can-Fite BioPharma issued a press release, which is summarized as follows: Can Fite’s liver drug candidate Namodenoson has been approved for compassionate use for the treatment of patients with advanced liver cancer in Romania. Namodenoson was previously approved for compassionate use in Israel, where advanced liver cancer patients have been treated for several years. In parallel, Can-Fite’s pivotal Phase III study in patients with advanced liver cancer (hepatocellular carcinoma), is open for patient enrolment and will recruit patients in Israel, the U.S., and five countries in Europe. This pivotal study received a ‘green light’ to proceed from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group through a subsidiary of the Company – a dermatology medical aesthetic company (“CMS Skinhealth”) made equity investment in Heling Medical (Guangzhou) Company Limited (禾零医药(广州)有限公司) (“Heling”) and obtained 60% equity interest in Heling (the “Equity Investment”). Following the Equity Investment, Heling became a subsidiary of the Company. Heling’s current products include Heling soothing moisturizing repair cream, Heling soothing repair lotion and Heling soothing moisturizing bath oil (the “Dermatology-grade Skincare Products” or the “Products”). On 19 August 2022, the Group through CMS Skinhealth entered into an Exclusive License Agreement with Heling for the Dermatology-grade Skincare Products. THE DERMATOLOGY-GRADE SKINCARE PRODUCTS The Dermatology-grade Skincare Products are composed of a variety of mild ingredients with Level-1 safety risk, containing no preservatives, mineral oil or alcohol. They […]
29th July 2022 – Blueberry Therapeutics issued a press release, which is summarized as follows: Blueberry Therapeutics are pleased to announce that recruitment into the Phase 2b European trial of BB2603 for fungal nail infection is now complete. This trial (BBTAF202) assesses the efficacy and safety of different doses of BB2603, a new topical anti-fungal formulation, in patients with fungal nail infection (onychomycosis). Data from the primary endpoint (an early response assessment at 16 weeks) are expected in Q1 2023, with final results to follow for the 52-week endpoints. Original Link: https://www.blueberrytherapeutics.com/blueberry-therapeutics-announce-recruitment-complet/
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 15 August 2022, the Group through a subsidiary of the Company–a Southeast Asian business company Rxilient Medical Pte. Ltd. (“Rxilient”) entered into a License, Collaboration and Supply Agreement (the “License Agreement”) with Hefei Tianmai Biotechnology Development Co., Ltd. (“HTBT”), a biopharmaceutical company, for the second-generation insulin series products and the third-generation insulin analogue glargine insulin injection (the “Insulin Products” or the “Products”). In accordance with the License Agreement, the Group through Rxilient gained an exclusive license to register, market, sell and distribute the Products in the eleven Southeast Asian countries (the “Territory”). The License Agreement will commence on its effective date and continue to be valid until the tenth anniversary of the date of the Products’ first commercialization in the Territory. Upon the expiration of the aforementioned term, […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 12 August 2022, the Group through certain subsidiaries of the Company (i) entered into a License, Collaboration and Distribution Agreement (the “License Agreement”) with EYE TECH CARE (“ETC”), a medical company of France, for EyeOP1® ultrasound glaucoma treatment device (the “EyeOP1® Glaucoma Treatment Device” or the “Product”) and (ii) made equity investment and acquired approximately 33.4% equity interest in ETC (the “Equity Investment”). In accordance with the Licence Agreement, the Group through its subsidiaries gained an exclusive license to import, export, develop, register, manufacture (subject to the terms and conditions as set out in the License Agreement) and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and the eleven Southeast Asian countries (the […]
Mean total Quality-of-Life scores in patients reporting data at one or more timepoints demonstrated a clinically important improvement during the 12-month study Reduced seizure worry and improved social functioning were the most significant findings July 20, 2022— Neurelis, Inc., issued a press release, which is summarized as follows: Seventy-two of 85 adult patients with seizure clusters who were enrolled in the long-term, Phase 3, open-label clinical trial of VALTOCO (diazepam nasal spray) reported stable or increased Quality of Life (QoL) during the study, according to recent findings published online in the leading journal, Epilepsy & Behavior. “These findings indicate that if we can reduce the number of seizure clusters with acute, rapid therapies, we potentially can have an impact on both seizure worry and social functioning.” said Adrian Rabinowicz, MD, SVP Clinical Development and Medical Affairs. Until now, limited research has been conducted to assess QoL as a potential secondary […]
The board (the “Board”) of directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 26 July 2022, the Group through a wholly-owned subsidiary of the Company – an ophthalmology business company (“CMS Ophthalmology”) entered into an Asset Transfer Agreement (the “Agreement”) with Wuhan YZY Biopharma Co., Ltd (“YZY Biopharma”), a biopharmaceutical company, to acquire all the assets related to VEGF/ANG2 tetravalent bispecific antibody for intravitreal injection (the “Bispecific Antibody Product”) in the world (the “Territory”) from YZY Biopharma (the “Acquisition”). In accordance with the Agreement, the assets related to the Bispecific Antibody Product in the Territory (the “Bispecific Antibody Product Assets”) include but are not limited to (i) all necessary rights and assets to use, develop, register, manufacture, commissioned manufacture, sell, distribute, promote and commercialize the Bispecific Antibody Product in the Territory and (ii) all intellectual property and intellectual property rights relevant to the Bispecific Antibody Product […]
On July 25, the China bridging trial of Methylthioninium Chloride Enteric-coated Sustained-release Tablets, an innovative medicine of China Medical System Holdings Limited (“CMS” or the “Group”), has completed the enrollment of all subjects. Since the first subject enrollment on January 10, the Group’s clinical research team has overcome challenges under pandemic prevention and control, and took only 6 months (including the Spring Festival Holiday) to complete the enrollment of all 1,800 subjects, which again proved the Group’s ability to efficiently enroll subjects for clinical trials.
Acticor Biotech is today announcing positive results from its ACTIMIS phase 1b/2a clinical trial using glenzocimab (an antibody targeting platelet GPVI ACT017) as an add-on to standard of care (thrombolysis with or without thrombectomy) in patients with Acute Ischemic Stroke (AIS).
Recently, the new drug application of Tildrakizumab solution for injection, the innovative biological product of China Medical System Holdings Limited (the “Group”), was approved in Hong Kong, China, with brand name of ILUMETRI.
On April 12, China Medical System Holdings
Limited completed the first subject dosing in China Phase III bridging trial of
its innovative medicine Methotrexate Injection, Pre-filled Syringe for adult
rheumatoid arthritis (RA) indication. This is another significant progress
following the product’s IND approval for RA indication in China, in August
2021.
On March 7, 2022, Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd., “Zydus”), a collaborative partner of China Medical System Holdings Limited (“CMS”), announced that it has received approval for its New Drug Application (NDA) from the Drug Controller General of India for OxemiaTM (Desidustat), a first-of-its-kind oral treatment in India for anemia associated with Chronic Kidney Disease (CKD). According to Zydus’ Press Release: “Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Desidustat met its primary endpoints for haemoglobin improvement in the DREAMD and DREAM-ND Phase III clinical trials and showed good safety profile, downregulation of hepcidin, improved iron mobilization and LDL-C reduction in CKD patients. The clinical development programme of Desidustat was one of the largest trials of its kind in India for Anemia in CKD patients, conducted in over 1200 subjects. Desidustat provides CKD patients with an oral convenient therapeutic option for the treatment of anemia. CKD […]
